There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD ... Chiesi also has a rival triple therapy approved in Europe.

COPD is term used to describe a number of progressive ... individuals to the treatment most likely to work for them.” The paper, ‘Single inhaler extra fine triple therapy versus long-acting muscarinic ...

Developed in partnership with Innoviva, Trelegy is the first ever daily single-inhaler to combine a triple therapy for COPD, and could help patients manage their condition better. Around a quarter ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

SAN DIEGO -- Tezepelumab (Tezspire) may hold potential as an add-on treatment for patients with chronic obstructive pulmonary disease (COPD) at high-risk for exacerbations, despite missing its ...

Bacterial colonisation is an important predictor of exacerbation in AATD-COPD and may require additional targeted therapy, study suggests.

Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have ...

Inhaled anticholinergic agents or SAMA such ... to LABA and/or LAMA primarily to prevent acute exacerbations of COPD. Triple Therapy. Patients with obstructive lung disease who have frequent ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...